- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06872905
Dataindsamling af den virkelige verden af Gore® Viabahn® VBX-ballonen Udvidelig endoprotese, når det bruges i dækket endovaskulær rekonstruktion af aorta-bifurcation (CERAB) til behandling af aortoiliac okklusiv sygdom
The study will assess the safety and effectiveness of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis ("VBX Device" or also referred to as "VBX Stent Graft") in a post approval setting and evaluate the quality of the use in covered endovascular reconstruction of the aortic bifurcation (CERAB) to treat Aortoiliac Occlusive Disease (AIOD).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
A minimum of 158 adult subjects will be enrolled at up to a minimum of 20 sites in the U.S. and Europe. Data will be collected retrospectively and found within existing site files at Baseline, Treatment, Discharge, Pre-12-Month Follow-up, 12-Month Follow-Up, Subsequent Follow-Up Visits.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Jennifer Camoriano, BS
- Telefonnummer: 14805365820
- E-mail: jcamoria@wlgore.com
Undersøgelse Kontakt Backup
- Navn: Chris Timberlake, BS
- Telefonnummer: 1-928-707-4974
- E-mail: ctimberl@wlgore.com
Studiesteder
-
-
-
Glasgow, Det Forenede Kongerige, G12 OXH
- Rekruttering
- Greater Glasgow Health Board
-
Kontakt:
- Martin Hennessy
-
Ledende efterforsker:
- Martin Hennessy, MD
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- Rekruttering
- University of Alabama at Birmingham
-
Kontakt:
- Benjamin Pearce, M.D.
- Telefonnummer: 205-934-2006
- E-mail: bjpearce@uabmc.edu
-
Kontakt:
- Rebecca St. John
- Telefonnummer: (205) 369-0363
- E-mail: rstjohn@uabmc.edu
-
-
California
-
Fresno, California, Forenede Stater, 93721
- Rekruttering
- University of California
-
Kontakt:
- Jessica Gallegos
-
Ledende efterforsker:
- Leigh Ann O'Banion, MD
-
-
Florida
-
Tampa, Florida, Forenede Stater, 33606
- Rekruttering
- University of South Florida
-
Kontakt:
- Charles Briggs, M.D.
- Telefonnummer: 813-505-4787
- E-mail: cbriggs@usf.edu
-
Kontakt:
- Beth Montera
- Telefonnummer: 1-813-844-7948
- E-mail: bmontera@usf.edu
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Rekruttering
- Mayo Clinic Rochester
-
Kontakt:
- Samantha Knight
-
Ledende efterforsker:
- Fahad Shuja, MBBS
-
-
New Jersey
-
Camden, New Jersey, Forenede Stater, 08103
- Rekruttering
- Cooper University Hospital
-
Kontakt:
- Jonelle O'Shea
-
Ledende efterforsker:
- Laurel Hastings, MD
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Rekruttering
- Rutgers
-
Kontakt:
- Marie Macor
-
Ledende efterforsker:
- William Beckerman, MD
-
-
New York
-
Buffalo, New York, Forenede Stater, 14203
- Rekruttering
- Research Foundation SUNY Buffalo
-
Ledende efterforsker:
- Linda Harris, MD
-
Kontakt:
- Dawn Holler
-
New York, New York, Forenede Stater, 10029
- Rekruttering
- Mount Sinai Medical Center
-
Ledende efterforsker:
- Ajit Rao, MD
-
Kontakt:
- Bridget Coyle
-
Syracuse, New York, Forenede Stater, 13210
- Rekruttering
- Research Foundation at SUNY Syracuse
-
Ledende efterforsker:
- Palma Shaw, MD
-
Kontakt:
- Maria Walker
-
Underforsker:
- Fawaz Araim, MD
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28203
- Rekruttering
- Atrium Health Sanger Heart & Vascular Institute
-
Kontakt:
- Houston Chapman
-
Ledende efterforsker:
- Hector Crespo-Soto, MD
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- Ohio State University Medical Center
-
Kontakt:
- Subhashish Das
-
Ledende efterforsker:
- Kyongjune Lee, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73112
- Rekruttering
- Integris Health Baptist Medical Center
-
Kontakt:
- Jones P Thomas, M.D.
- Telefonnummer: 405-951-4345
- E-mail: Jones.thomas@integrishealth.org
-
Kontakt:
- Natalie VanBuskirk
- E-mail: natalie.vanbuskirk@integrishealth.org
-
-
Pennsylvania
-
Danville, Pennsylvania, Forenede Stater, 17822
- Rekruttering
- Geisinger Medical Center
-
Kontakt:
- Rebecca Mack
-
Ledende efterforsker:
- Evan Ryer, MD
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- University Of Pennsylvania
-
Ledende efterforsker:
- Grace WANG, MD
-
Kontakt:
- Carolina Reyes
-
-
South Dakota
-
Sioux Falls, South Dakota, Forenede Stater, 57105
- Rekruttering
- Sanford Clinical Vascular Associates
-
Kontakt:
- Karla Reily
-
Ledende efterforsker:
- Anand Dayama, MD
-
-
Tennessee
-
Kingsport, Tennessee, Forenede Stater, 37760
- Rekruttering
- Wellmont Holston Valley Medical Center
-
Kontakt:
- Ashley Bowen
-
Ledende efterforsker:
- Ryan Cronin, MD
-
Nashville, Tennessee, Forenede Stater, 37232
- Afsluttet
- Vanderbilt University Medical Center
-
-
Texas
-
Austin, Texas, Forenede Stater, 78712
- Rekruttering
- The University of Texas Austin
-
Kontakt:
- Andrea Stapper
-
Ledende efterforsker:
- Meryl Logan, MD
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- Rekruttering
- University of Virginia
-
Kontakt:
- Robin Kelly
-
Ledende efterforsker:
- Behzad Farivar, MD
-
Roanoke, Virginia, Forenede Stater, 24016
- Rekruttering
- Carilion Clinic
-
Kontakt:
- Yili Zhong
-
Ledende efterforsker:
- Esmaeel Dadashzadeh, MD
-
-
Wisconsin
-
Marshfield, Wisconsin, Forenede Stater, 54449
- Rekruttering
- Marshfield Medical Center - Marshfield
-
Kontakt:
- Angela Varsho
-
Ledende efterforsker:
- Shameem Kunhammed, MD
-
-
-
-
-
Amsterdam, Holland, 1105
- Rekruttering
- Amsterdam UMC Research BV
-
Kontakt:
- Rutger Lely
-
Ledende efterforsker:
- Rutger Lely, MD
-
Rotterdam, Holland, 3045 PM
- Rekruttering
- Franciscus
-
Kontakt:
- Jerome van Brussel
-
Ledende efterforsker:
- Jerome van Brussel, MD
-
-
-
-
-
Padova, Italien, 35131
- Ikke rekrutterer endnu
- Azienda Ospedaliero-Universitaria di Padova
-
Kontakt:
- Michele Antonello, M.D.
- Telefonnummer: +39 0498218736
- E-mail: michele.antonello.1@unipd.it
-
Varese, Italien, 21100
- Rekruttering
- Ospedale di Circolo e Fondazione Macchi
-
Kontakt:
- Gabriele Piffaretti
-
Ledende efterforsker:
- Gabriel Piffaretti, MD
-
-
-
-
-
Alicante, Spanien, 03010
- Rekruttering
- Hospital General Universitario de Alicante
-
Kontakt:
- Elisabeth Cruces Fuentes
-
Ledende efterforsker:
- Elisabeth Cruces Fuentes, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
As described in the background section, patients with aortoiliac occlusive disease are treated with various surgical and endovascular therapies to improve arterial blood flow to the lower extremity. This study will retrospectively evaluate a population of patients that have had covered endovascular reconstruction of the aortic bifurcation (CERAB) with GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.
The study has been designed with standard eligibility criteria to evaluate the safety and effectiveness of the VBX Device when used in a CERAB for an aortoiliac occlusive disease patient population.
Considering the nature of aortoiliac occlusive disease, elderly patients (≥ 65 years old) can represent a significant number of patients enrolled in this study. This population can include patients with cognitive disorder or severe dementia.
According to EU regulation, elderly patients are considered vulnerable population. However, considering the retrospective nature of the study design, t
Beskrivelse
Inclusion Criteria:
- Patient treated with covered endovascular reconstruction of the aortic bifurcation (CERAB) procedure for aortoiliac occlusive disease (AIOD).
- Patient was implanted with the VBX Device in the aortic position during a CERAB procedure.
- Patient was treated with the CERAB procedure a minimum of 1 year before enrollment date.
- Age ≥18 years at the time of CERAB procedure.
- Obtain patient informed consent or waiver according to local Institutional Review Board (IRB)/Ethics Committee (EC) -
Exclusion Criteria:
-
Patient with prior stenting in the aortic or common iliac artery at the time of CERAB procedure.
-
Patient treated with concomitant chimney procedure at time of CERAB procedure (e.g., inferior mesenteric artery, renal artery).
-
Participation in another drug or device investigational study at the time of the CERAB procedure date that can confound the study endpoints.
-
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: RETROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
GORE VIABAHN® VBX Balloon Expandable Endoprosthesis
Patient was implanted with the VBX Device in the aortic and common iliac positions during the CERAB procedure. |
Treatment of Target Lesions with the VBX Device in the aortic and common iliac positions during the CERAB procedure. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary Effectiveness Endpoint: 1-Year Primary patency (hypothesis testing)
Tidsramme: 1-Year
|
Proportion of patients maintaining primary patency at 1 Year |
1-Year
|
|
Primary Safety Endpoint: 30-day Morbidity (hypothesis testing)
Tidsramme: 30-Day
|
Proportion of patients experiencing any major adverse cardiovascular event (i.e. myocardial infarction, cerebrovascular accident) or event requiring reintervention. |
30-Day
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Technical Success
Tidsramme: At index procedure
|
Proportion of patients with technical success |
At index procedure
|
|
Mortality
Tidsramme: 30-Day
|
Proportion of patients with all cause death |
30-Day
|
|
Device Integrity
Tidsramme: 1 year
|
Proportion of patients achieving Primary Patency |
1 year
|
|
Primary assisted patency
Tidsramme: 1 year
|
Proportion of patients achieving Primary Assisted patency |
1 year
|
|
Secondary patency
Tidsramme: 1 year
|
Proportion of patients achieving Secondary Patency |
1 year
|
|
Freedom from Target Lesion Revascularization
Tidsramme: 1 year
|
Proportion of patients achieving freedom from Target Lesion Revascularization |
1 year
|
|
Survival
Tidsramme: 1 Year
|
Proportion of patients survival |
1 Year
|
|
Freedom from Clinically-Driven Target Lesion Revascularization
Tidsramme: 1 year
|
Proportion of patients achieving freedom from Clinically-Driven Target Revascularization |
1 year
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Leigh Ann O'Banion, M.D., University of California, San Francisco
- Ledende efterforsker: Michele Antonello, M.D., Azienda Ospedaliero-Universitaria di Padova
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- VBX 24-03
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .